Catalog No. : CBB-F011003-C
ClearCell® FX1 System CE IVD
- Label-Free Liquid Biopsy System
- Label-free CTC enrichment fo heterogeneous populations of cancer cells
- Up to 10,000x enrichment of CTCs that are wholly intact and viable
- Large blood volume enrichment from 7.5ml of patients' blood
- Automated workflow and fast processing time of < 1h
- Sensitive, with a high dynamic range
- Easy and ready integration with a wide variety of downstream molecular and pathology applications
- CE-IVD and ISO 13485 certified
|ClearCell® FX1 System CE IVD||
|Cell Culture Automation||Please Inquire|
ClearCell® FX1 Unit CE-IVD x 1
ClearCell® FX1 Installation Run Kit CE-IVD x 1
FX System Warranty (1st year)
Fluorescence In Situ Hybridisation (FISH)
Fluorescence in situ hybridisation (FISH) is an established cytogenetic technique used in pathology laboratories for tumour profiling and screening of genetic aberrations, such as gene translocation, amplification and deletions. It is also the current gold standard for selection of cancer patient eligible for HER2 and ALK targeted drug therapy. …
The emergence of novel technologies offers a new avenue to obtain circulating tumour cells (CTCs) for understanding metastasis. CTCs are extremely rare in circulation and the isolation of intact and viable cells is non-trivial. Use of affinity based methods and magnetic beads based methods could potentially impact cellular phenotypes and viability …
KRAS is an oncogene with extremely high incidence of mutations. KRAS mutations have been seen in approximately 25% of all cancer types and 30-40% of colorectal cancer (Arrington et al. 2012). It is also associated with poorer prognosis and treatment response in colorectal and lung cancer. As such, there is significant interest in molecular testing of KRAS mutation. …
Immunofluorescence (IF) / Immunocytochemistry (ICC)
This application note describes the label-free enrichment of CTCs or microemboli from blood sample using the ClearCell® FX platform followed by immunofluorescence assay
Contact Us at email@example.com for more information.
- Arutha Kulasinghe, Chris Perry, Liz Kenny, Tony Blick, Majid Warkiani, Ian Vela, Ken O'Byrne, Jean-Paul Thiery, Erik Thompson, Colleen Nelson, Chamindie Punyadeera. Circulating tumor cells: The tumor trail left in the blood [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5572.
- Chen et al., 2018, “Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy” Molecular Cancer Research, December 2018 Volume 16, Issue 12.
- Garcia et al., 2018, “Comparison of OncoBEAM and NGS methods to do plasma EGFR p.T790M mutation during progression in non small cell Lung cancer”, ESMO 2018.
- Lee et al. 2018, “ClearCell® FX, a label‐free microfluidics technology for enrichment of viable circulating tumor
- Ramalingam et al., 2018, “Marker-Free microfluidic enrichment enables full-length mRNA transcriptome analysis of single live circulating tumors cells from six Breast cancer subjects, Single Cell Genomics 2018.
- Schneegans et al., 2018, “Impact of Blood Collection Tubes on CTC-, ctDNA- and miRNA recoveries in malignant melanoma patients” AACR Annual Meeting 2018
- Xu et al., 2018, “Xenograft tumors derived from malignant pleural efusion of the patients with non- small-cell lung cancer as models to explore drug resistance”, Cancer Communications2018: 38:19
- Yin et al. 2018, “Characterization of circulating tumor cells in breast cancer patients by spiral microfluidics”